AUPH Aurinia Pharmaceuticals Forecast, Technical & Fundamental Analysis
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs... Show more
AUPH is expected to report earnings to fall 15.00% to 23 cents per share on October 29
Q3'26
Est.
$0.24
Q2'26
Beat
by $0.05
Q1'26
Beat
by $0.06
Q4'25
Beat
by $1.38
Q3'25
Beat
by $0.07
The last earnings report on August 06 showed earnings per share of 28 cents, beating the estimate of 23 cents. With 700.77K shares outstanding, the current market capitalization sits at 2.22B.
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics
A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with KALA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then KALA could also see price increases.
AUPH in upward trend: price rose above 50-day moving average on August 19, 2026
AUPH moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend. In of 46 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 06, 2026. You may want to consider a long position or call options on AUPH as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AUPH just turned positive on August 06, 2026. Looking at past instances where AUPH's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AUPH moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for AUPH crossed bearishly below the 50-day moving average on July 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AUPH broke above its upper Bollinger Band on August 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AUPH entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.602) is normal, around the industry mean (20.145). P/E Ratio (7.303) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (7.289) is also within normal values, averaging (444.692).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
